ESM1 and glioblastoma: However, similar to the results earlier obtained in a clinical trial of the anti-angiogenic drug bevacizumab which failed to improve overall survival of GBM patients due to metabolic reprograming78, glioblastoma cells can easily adapt to the absence of Endocan by using alternative signaling pathways.